Today's news and events

Market

Spotlight

DRREDDYSpotlight

Dr Reddy's Labs Q1 PAT plunges 69% YoY to Rs 444 crore

Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in the quarter ended 30 June 2026. Profit before tax (PBT) dropped 70.98% YoY to Rs 552.6 crore in Q1 FY27. EBITDA slipped 55.72% to Rs 1,008.8 crore in Q1 FY27 compared with Rs 2,278.4 crore in Q1 FY26. EBITDA margin contracted to 12.5% in Q1 FY27 as against 26.7% in Q1 FY26. Revenue from the Global Generics segment declined 4.79% year-on-year to Rs 7,199.3 crore during the quarter. Revenue from the North America business fell 35.38% YoY to Rs 2,204.8 crore, mainly due to lower sales of Lenalidomide. The company launched six new products in the region during the quarter. Revenue from the India business increased 16.76% YoY to Rs 1,717.7 crore, supported by new brand launches, including innovative assets and recently acquired portfolios, along with price increases and higher sales volumes. The company launched seven new brands during the quarter. Revenue from the Europe region grew 13.30% YoY to Rs 1,444 crore, aided by the launch of 24 new generic products. The Emerging Markets segment reported a 30.52% YoY growth in revenue to Rs 1,832.8 crore, driven by new launches, higher volumes and favourable foreign exchange movement. Research and Development (R&D) expenditure stood at Rs 580 crore in Q1 FY27, down 8% year-on-year but up 6% sequentially. R&D expenses accounted for 7.1% of revenue during the quarter, compared with 7.3% in Q1 FY26. The decline was primarily due to lower development spending on biosimilars, while investments remained focused on complex generics, including peptides and biosimilars. Co-Chairman & MD, G V Prasad, said: Our Q1 FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. However, our underlying base business continued to deliver healthy doubledigit growth across all key geographies. Our focus remains on improving the health of our base business through disciplined execution and operational excellence, while building our future pipeline of peptides, biosimilars, and innovative assets to deliver long-term growth. Meanwhile, the company's board approved the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel and her induction as a member of the Management Council, effective 22 July 2026. Hyderabad-based Dr Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The scrip slipped 1.95% to settle at Rs 1,183 on the BSE. Powered by Capital Market - Live

7 hours agoCapital Market - Live

Corporate

APOLLOCorporate

Apollo Micro Systems awarded Prototype Sanction Order by Indian Navy

Apollo Micro Systems has been shortlisted and awarded a Make-II Prototype Sanction Order (PSO) by the Indian Navy, in recognition of the Company's established capabilities in indigenous Naval Maritime Electronic Warfare. The project pertains to the design, development, and prototype demonstration of the Semi-Submersible Autonomous Vessel for Intelligence, Operations and Reconnaissance (SAVIOR-ASW) under the Make-II category. SAVIOR-ASW is an unmanned, semi-submersible maritime platform designed for persistent Anti-Submarine Warfare (ASW) surveillance, capable of autonomous operations for extended durations using advanced acoustic sensors, AI/ML-based target classification, and encrypted multi-channel communication systems. The system represents a significant step forward in India's indigenous underwater warfare capability. This is a prestigious and landmark order for the Company marking its formal entry into the domain of autonomous maritime and underwater warfare systems. In accordance with the Make-II category, there is no cost obligation on the Government during the prototype development phase. The Government is committed to procurement upon successful demonstration of the prototype.

7 hours agoCapital Market - Live

PRECAM Cash Dividend

Ex DateJul 23, 2026

Final • Dividend/Share : ₹1.00

Corporate

SRFCorporate

Board of SRF approves setting up BOPET Thick Film Line

The board of SRF at its meeting held on 22 July 2026 has approved the proposal to set up a BOPET Thick Film Line at a projected cost of Rs. 250 crore.

7 hours agoCapital Market - Live

Corporate

SHYAMMETLCorporate

Shyam Metalics & Energy fixes record date for final dividend

Shyam Metalics & Energy has fixed 07 August 2026 as record date for final dividend for FY 2025-26.

7 hours agoCapital Market - Live

See All

NIFTY 50		23,991.250.81%
USD/INR		96.620.33%
Gold		15,164.431.37%

NIFTY 100 Largecap		25,065.150.78%
NIFTY 100 Midcap		62,288.101.11%
NIFTY 100 Smallcap		19,124.751.56%

NIFTY Bank		57,122.101.23%
NIFTY IT		28,524.901.59%
NIFTY Pharma		25,751.151.31%

STOCKSPRICECHANGE
Bajaj Auto LtdBAJAJ-AUTO	₹10,998.505.72%
TVS Motor Company LtdTVSMOTOR	₹3,907.603.05%
Nestle India LtdNESTLEIND	₹1,493.602.87%
Polycab India LtdPOLYCAB	₹9,090.502.10%
Bosch LtdBOSCHLTD	₹41,560.001.69%

FUNDSRETURNS
Quant Large Cap Fund Equity • Growth 8.67%
Bank of India Large Cap Fund Equity • Growth 5.86%
Invesco India Largecap Fund Equity • Growth 4.17%
Taurus Large Cap Fund Equity • Growth 3.62%
Tata Large Cap Fund Equity • Growth 3.31%

Tickertape - Financial freedom begins here

Market and sectors

Today's stocks

Mutual funds and ETFs

Ready-made Portfolios

Curated screens and deals

Stock Screens

Deals

Mutual Fund Screens